Cesar Augusto Perez, MD, medical oncologist, director, Drug Development, Florida Cancer Specialists & Research Institute, Sarah Cannon Research Institute, discusses the potential utility of KIN-2787 in 

KIN-2787 is an investigational, next-generation, pan-RAF inhibitor being evaluated for patients with solid tumors harboring class I, II, and III 

 mutations, Perez explains. The agent was specifically developed to target class II and III mutations, which is an area of significant unmet need in patients with 

KIN-2787 is being evaluated in an ongoing phase 1 trial (NCT04913285) for adult patients with 

-mutated solid tumors, including non–small cell lung cancer and melanoma, Perez says. This drug is unique because most available agents for patients with 

-mutated diseases were designed to target class I mutations. As such, the results of this study will be intriguing as KIN-2787 could have clinical utility across 

 mutation–positive subgroups, Perez concludes. 

Videos

Cesar Augusto Perez, MD, discusses the potential utility of KIN-2787 in BRAF-mutated solid tumors. 

Cesar Augusto Perez, MD

Articles

Dr. Perez on the Potential Utility of KIN-2787 in BRAF-Mutated Solid Tumors